US Bancorp’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-27,244
| Closed | -$128K | – | 4272 |
|
|
2024
Q3 | $128K | Sell |
27,244
-1,143
| -4% | -$6.13K | ﹤0.01% | 2276 |
|
|
2024
Q2 | $160K | Hold |
28,387
| – | – | ﹤0.01% | 2106 |
|
|
2024
Q1 | $117K | Sell |
28,387
-2,529
| -8% | -$10.1K | ﹤0.01% | 2277 |
|
|
2023
Q4 | $130K | Buy |
30,916
+30,555
| +8,464% | +$123K | ﹤0.01% | 2223 |
|
|
2023
Q3 | $1.56K | Sell |
361
-2,607
| -88% | -$14.5K | ﹤0.01% | 3699 |
|
|
2023
Q2 | $19.6K | Buy |
2,968
+2,607
| +722% | +$16.7K | ﹤0.01% | 2989 |
|
|
2023
Q1 | $2.45K | Sell |
361
-138
| -28% | -$970 | ﹤0.01% | 3705 |
|
|
2022
Q4 | $3.69K | Hold |
499
| – | – | ﹤0.01% | 3616 |
|
|
2022
Q3 | $5K | Sell |
499
-1,032
| -67% | -$10.9K | ﹤0.01% | 3626 |
|
|
2022
Q2 | $17K | Buy |
1,531
+480
| +46% | +$4.97K | ﹤0.01% | 3153 |
|
|
2022
Q1 | $12K | Buy |
1,051
+844
| +408% | +$11.1K | ﹤0.01% | 3320 |
|
|
2021
Q4 | $3K | Hold |
207
| – | – | ﹤0.01% | 3837 |
|
|
2021
Q3 | $4K | Sell |
207
-639
| -76% | -$11.2K | ﹤0.01% | 3735 |
|
|
2021
Q2 | $18K | Hold |
846
| – | – | ﹤0.01% | 3202 |
|
|
2021
Q1 | $13K | Buy |
846
+400
| +90% | +$6.47K | ﹤0.01% | 3205 |
|
|
2020
Q4 | $6K | Sell |
446
-478
| -52% | -$5.75K | ﹤0.01% | 3369 |
|
|
2020
Q3 | $9K | Sell |
924
-611
| -40% | -$6.53K | ﹤0.01% | 3128 |
|
|
2020
Q2 | $17K | Sell |
1,535
-514
| -25% | -$5.82K | ﹤0.01% | 2896 |
|
|
2020
Q1 | $22K | Sell |
2,049
-1,213
| -37% | -$15K | ﹤0.01% | 2714 |
|
|
2019
Q4 | $53K | Sell |
3,262
-3,364
| -51% | -$50.9K | ﹤0.01% | 2456 |
|
|
2019
Q3 | $88K | Sell |
6,626
-19,741
| -75% | -$275K | ﹤0.01% | 2226 |
|
|
2019
Q2 | $372K | Sell |
26,367
-13,686
| -34% | -$218K | ﹤0.01% | 1548 |
|
|
2019
Q1 | $737K | Buy |
40,053
+6,845
| +21% | +$156K | ﹤0.01% | 1207 |
|
|
2018
Q4 | $868K | Buy |
33,208
+6,118
| +23% | +$144K | ﹤0.01% | 1084 |
|
|
2018
Q3 | $621K | Buy |
27,090
+26,782
| +8,695% | +$547K | ﹤0.01% | 1343 |
|
|
2018
Q2 | $6K | Buy |
308
+148
| +93% | +$2.48K | ﹤0.01% | 3291 |
|
|
2018
Q1 | $3K | Sell |
160
-3,064
| -95% | -$51.3K | ﹤0.01% | 3438 |
|
|
2017
Q4 | $49K | Buy |
3,224
+2,924
| +975% | +$43.4K | ﹤0.01% | 2613 |
|
|
2017
Q3 | $5K | Hold |
300
| – | – | ﹤0.01% | 3276 |
|
|
2017
Q2 | $5K | Hold |
300
| – | – | ﹤0.01% | 3239 |
|
|
2017
Q1 | $4K | Buy |
+300
| New | +$4.28K | ﹤0.01% | 3275 |
|
Other funds holding VNDA
TCM
US Bancorp's VNDA Position: Q4 2024 in Review
US Bancorp sold out of Vanda Pharmaceuticals (VNDA) in Q4 2024, closing a stake of 27,244 shares — an estimated $128K sold.
US Bancorp first reported a position in VNDA in Q1 2017 and held it in 31 quarters. The position peaked at $868K in Q4 2018. 146 funds tracked by Wall St. Rank hold VNDA as of Q4 2024.
- US Bancorp reported no remaining Vanda Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
- US Bancorp sold 27,244 Vanda Pharmaceuticals shares in Q4 2024, an estimated $128K.
- US Bancorp first reported a position in Vanda Pharmaceuticals in Q1 2017 and held it in 31 quarters.
- US Bancorp's Vanda Pharmaceuticals position peaked at $868K in Q4 2018.
- 146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2024.
Based on US Bancorp's 13F filing for Q4 2024, filed 5 Feb 2025.